Insider Selling: GeneDx Holdings Corp. (NASDAQ:WGS) CFO Sells 1,104 Shares of Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley sold 1,104 shares of the business’s stock in a transaction dated Monday, April 29th. The stock was sold at an average price of $11.04, for a total transaction of $12,188.16. Following the sale, the chief financial officer now owns 30,836 shares in the company, valued at $340,429.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Kevin Feeley also recently made the following trade(s):

• On Monday, March 18th, Kevin Feeley sold 3,253 shares of GeneDx stock. The shares were sold at an average price of $10.59, for a total value of $34,449.27.

GeneDx Trading Up 55.2 %

NASDAQ:WGS traded up $6.07 during trading hours on Tuesday, reaching $17.07. 7,282,556 shares of the company were exchanged, compared to its average volume of 325,185. The firm has a market cap of $444.67 million, a price-to-earnings ratio of -2.25 and a beta of 2.75. The company has a debt-to-equity ratio of 0.23, a current ratio of 3.10 and a quick ratio of 2.95. The stock has a 50 day simple moving average of $9.39 and a 200 day simple moving average of $5.09. GeneDx Holdings Corp. has a 52-week low of $1.16 and a 52-week high of $18.24.

GeneDx (NASDAQ:WGS) last announced its earnings results on Tuesday, February 20th. The company reported ($0.59) earnings per share for the quarter, beating the consensus estimate of ($0.60) by $0.01. GeneDx had a negative return on equity of 49.64% and a negative net margin of 86.77%. The company had revenue of $57.42 million during the quarter, compared to the consensus estimate of $57.00 million. As a group, analysts predict that GeneDx Holdings Corp. will post -2.02 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Thompson Davis & CO. Inc. grew its holdings in GeneDx by 99.4% during the fourth quarter. Thompson Davis & CO. Inc. now owns 19,944 shares of the company’s stock worth $55,000 after acquiring an additional 9,944 shares during the period. PFG Investments LLC acquired a new stake in shares of GeneDx during the first quarter worth $95,000. Pathstone Family Office LLC lifted its holdings in shares of GeneDx by 262.2% during the third quarter. Pathstone Family Office LLC now owns 54,327 shares of the company’s stock valued at $198,000 after purchasing an additional 39,327 shares during the last quarter. Decheng Capital LLC acquired a new position in shares of GeneDx in the 4th quarter valued at $285,000. Finally, Trellus Management Company LLC raised its holdings in GeneDx by 55.0% during the 3rd quarter. Trellus Management Company LLC now owns 155,012 shares of the company’s stock worth $564,000 after buying an additional 54,976 shares during the period. Institutional investors and hedge funds own 61.72% of the company’s stock.

Analyst Ratings Changes

WGS has been the topic of several recent research reports. The Goldman Sachs Group boosted their price target on GeneDx to $11.00 and gave the company a “neutral” rating in a research report on Monday, April 15th. BTIG Research upped their price target on shares of GeneDx from $15.00 to $19.00 and gave the company a “buy” rating in a report on Tuesday. Finally, TD Cowen lifted their price objective on GeneDx from $14.00 to $24.00 and gave the stock a “buy” rating in a research report on Tuesday.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.